Publication: Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
dc.conference.date | MAY 03-05, 2022 | |
dc.conference.title | European-Society-for-Medical-Oncology (ESMO) Breast Cancer Congress | |
dc.contributor.author | Gebhart, G. | |
dc.contributor.author | Keyaerts, M. | |
dc.contributor.author | Guiot, T. | |
dc.contributor.author | Flamen, P. | |
dc.contributor.author | Ruiz Borrego, M. | |
dc.contributor.author | Stradella, A. | |
dc.contributor.author | Bermejo De Las Heras, B. | |
dc.contributor.author | Escriva de Romani, S. | |
dc.contributor.author | Calvo-Martinez, L. | |
dc.contributor.author | Ribelles Entrena, N. | |
dc.contributor.author | Martinez, N. | |
dc.contributor.author | Albacar Miro, C. R. | |
dc.contributor.author | Colleoni, M. A. | |
dc.contributor.author | Atienza de Frutos, M. | |
dc.contributor.author | Sampayo-Cordero, M. | |
dc.contributor.author | Cortes, J. | |
dc.contributor.author | Perez Garcia, J. M. | |
dc.contributor.author | Llombart Cussac, A. | |
dc.contributor.authoraffiliation | [Gebhart, G.] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium | |
dc.contributor.authoraffiliation | [Guiot, T.] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium | |
dc.contributor.authoraffiliation | [Flamen, P.] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium | |
dc.contributor.authoraffiliation | [Keyaerts, M.] UZ Brussel Univ Ziekenhuis Brussel, Dept Nucl Med, Jette, Belgium | |
dc.contributor.authoraffiliation | [Ruiz Borrego, M.] Hosp Virgen Rocio Sevilla, Dept Oncol, Seville, Spain | |
dc.contributor.authoraffiliation | [Stradella, A.] ICO Inst Catala Oncol Hosp Hosp Duran, Dept Med Oncol, Lhospitalet De Llobregat, Spain | |
dc.contributor.authoraffiliation | [Bermejo De Las Heras, B.] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain | |
dc.contributor.authoraffiliation | [Escriva de Romani, S.] Vall dHebron Univ Hosp, Breast Canc Unit, Med Oncol, Barcelona, Spain | |
dc.contributor.authoraffiliation | [Calvo-Martinez, L.] CHUAC Complexo Hosp Univ Coruna, Dept Oncol, La Coruna, Spain | |
dc.contributor.authoraffiliation | [Ribelles Entrena, N.] Hosp Univ Virgen Victoria, UGCI Oncol Intercentros, Malaga, Spain | |
dc.contributor.authoraffiliation | [Martinez, N.] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain | |
dc.contributor.authoraffiliation | [Albacar Miro, C. R.] Hosp Univ St Joan Reus, Oncol Dept ment, Reus, Spain | |
dc.contributor.authoraffiliation | [Colleoni, M. A.] IEO Ist Europeo Oncol, Divis Med Senol, Milan, Italy | |
dc.contributor.authoraffiliation | [Atienza de Frutos, M.] Univ Europea Madrid, Dept Oncol, Villaviciosa De Odon, Spain | |
dc.contributor.authoraffiliation | [Sampayo-Cordero, M.] Med Scientia Innovat Res MEDSIR, Dept Med, Barcelona, Spain | |
dc.contributor.authoraffiliation | [Cortes, J.] Int Breast Canc Ctr IBCC, Dept Oncol, Quiron Grp, Madrid, Spain | |
dc.contributor.authoraffiliation | [Perez Garcia, J. M.] Int Breast Canc Ctr IBCC, Dept Med Oncol, Quiron Grp, Barcelona, Spain | |
dc.contributor.authoraffiliation | [Llombart Cussac, A.] Hosp Arnau Vilanova, Med Oncol Dept, Valencia, Spain | |
dc.date.accessioned | 2023-05-03T14:40:06Z | |
dc.date.available | 2023-05-03T14:40:06Z | |
dc.date.issued | 2022-05-05 | |
dc.identifier.doi | 10.1016/j.annonc.2022.03.109 | |
dc.identifier.essn | 1569-8041 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.unpaywallURL | http://www.annalsofoncology.org/article/S0923753422004884/pdf | |
dc.identifier.uri | http://hdl.handle.net/10668/21902 | |
dc.identifier.wosID | 792494100095 | |
dc.issue.number | 3 | |
dc.journal.title | Annals of oncology | |
dc.journal.titleabbreviation | Ann. oncol. | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Virgen de la Victoria | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.page.number | S166-S166 | |
dc.publisher | Elsevier | |
dc.rights.accessRights | open access | |
dc.title | Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial | |
dc.type | conference output | |
dc.type.hasVersion | VoR | |
dc.volume.number | 33 | |
dc.wostype | Meeting Abstract | |
dspace.entity.type | Publication |